NCT03091192 2026-04-14Savolitinib vs. Sunitinib in MET-driven PRCC.AstraZenecaPhase 3 Active not recruiting60 enrolled 15 charts
NCT02928406 2024-04-04A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary TractHoffmann-La RochePhase 3 Completed1,004 enrolled 39 charts
NCT01310803 2017-10-05Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the BladderEndo PharmaceuticalsPhase 3 Terminated1 enrolled 5 charts